Sumanto Mukhopadhyay
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sumanto Mukhopadhyay has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Andreas Baumbach
Barts Heart Centre, St Bartholomew's Hospital, London, United Kingdom; Centre for Cardiovascular Medicine and Devices, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom
1 shared publication - Anthony Mathur
Centre for Cardiovascular Medicine and Devices, William Harvey Research Institute, Queen Mary University of London
1 shared publication Guy Lloyd
1 shared publication- Kush P. Patel
Barts Heart Centre, St Bartholomew’s Hospital, London, United Kingdom (K.P.P., A.B.).
1 shared publication - Michael J. Mullen
St Bartholomew’s Hospital
1 shared publication - Michael McKenna
Barts Heart Centre, St Bartholomew’s Hospital , West Smithfield, London EC1A 7BE
1 shared publication
Latest Publications
- 1 August 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 18 (8) , e014915
Shorter Time to Transcatheter Aortic Valve Implantation Is Associated With Improved Outcomes in Acute Decompensated Aortic Stenosis
BACKGROUND: Acute decompensated aortic stenosis is an increasingly common condition associated with a high rate of morbidity, mortality, and health care resource utilization. Among patients with acute decompensated aortic stenosis, this study aimed to assess the impact of time to transcatheter aortic valve implantation (TAVI) on outcomes, hypothesizing that longer durations are associated with worse outcomes. METHODS: Using a single-center registry, patients with their first presentation of acute decompensated aortic stenosis who underwent an urgent TAVI during their index admission were included. Time to TAVI was defined as the number of days between hospital admission and TAVI. The primary composite outcome was heart failure hospitalization or all-cause mortality. The secondary composite outcome was heart failure hospitalization or cardiovascular mortality. RESULTS: A total of 276 patients were included in this study: age 84 (79–88) years, male sex 63.7%, patients requiring cardiopulmonary organ support 3.6%, aortic valve area 0.7 (0.5–0.8) cm 2 , and left ventricular ejection fraction 55 (37–57)%. Baseline characteristics were similar between patients stratified according to the median time to TAVI (22 [13–32] days). Over a follow-up of 4.6 (3.6–5.7) years, the primary and secondary outcomes occurred in 58% and 35% of patients, respectively. After adjusting for comorbidities, mean gradient, and cardiopulmonary organ support, time to TAVI was associated with both the primary (hazard ratio for every 5 days, 1.09 [95% CI, 1.04–1.16]; P =0.001) and secondary outcomes (hazard ratio for every 5 days, 1.08 [95% CI, 1.01–1.16]; P =0.023). CONCLUSIONS: In patients with acute decompensated aortic stenosis, longer time to TAVI was associated with an increased risk of adverse events at mid-term follow-up.
- 1 August 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 18 (8) , e014915
Shorter Time to Transcatheter Aortic Valve Implantation Is Associated With Improved Outcomes in Acute Decompensated Aortic Stenosis
BACKGROUND: Acute decompensated aortic stenosis is an increasingly common condition associated with a high rate of morbidity, mortality, and health care resource utilization. Among patients with acute decompensated aortic stenosis, this study aimed to assess the impact of time to transcatheter aortic valve implantation (TAVI) on outcomes, hypothesizing that longer durations are associated with worse outcomes. METHODS: Using a single-center registry, patients with their first presentation of acute decompensated aortic stenosis who underwent an urgent TAVI during their index admission were included. Time to TAVI was defined as the number of days between hospital admission and TAVI. The primary composite outcome was heart failure hospitalization or all-cause mortality. The secondary composite outcome was heart failure hospitalization or cardiovascular mortality. RESULTS: A total of 276 patients were included in this study: age 84 (79–88) years, male sex 63.7%, patients requiring cardiopulmonary organ support 3.6%, aortic valve area 0.7 (0.5–0.8) cm 2 , and left ventricular ejection fraction 55 (37–57)%. Baseline characteristics were similar between patients stratified according to the median time to TAVI (22 [13–32] days). Over a follow-up of 4.6 (3.6–5.7) years, the primary and secondary outcomes occurred in 58% and 35% of patients, respectively. After adjusting for comorbidities, mean gradient, and cardiopulmonary organ support, time to TAVI was associated with both the primary (hazard ratio for every 5 days, 1.09 [95% CI, 1.04–1.16]; P =0.001) and secondary outcomes (hazard ratio for every 5 days, 1.08 [95% CI, 1.01–1.16]; P =0.023). CONCLUSIONS: In patients with acute decompensated aortic stenosis, longer time to TAVI was associated with an increased risk of adverse events at mid-term follow-up.